Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386601467> ?p ?o ?g. }
- W4386601467 endingPage "1469" @default.
- W4386601467 startingPage "1469" @default.
- W4386601467 abstract "The rapid evolution of new SARS-CoV-2 variants poses a continuing threat to human health. Vaccination has become the primary therapeutic intervention. The goal of the current work was the construction of immunogenic virus-like particles (VLPs). Here, we describe a human cell line for cost-efficient and scalable production of immunogenic SARS-CoV-2 VLPs. The modular design of the VLP-production platform facilitates rapid adaptation to new variants. Methods: The N, M-, and E-protein genes were integrated into the genome of Expi293 cells (ExpiVLP_MEN). Subsequently, this cell line was further modified for the constitutive expression of the SARS-CoV-2 spike protein. The resulting cell line (ExpiVLP_SMEN) released SARS-CoV-2 VLP upon exposure to doxycycline. ExpiVLP_SMEN cells were readily adapted for VLP production in a 5 L bioreactor. Purified VLPs were quantified by Western blot, ELISA, and nanoparticle tracking analysis and visualized by electron microscopy. Immunogenicity was tested in mice. Results: The generated VLPs contained all four structural proteins, are within the size range of authentic SARS-CoV-2 virus particles, and reacted strongly and specifically with immunoserum from naturally infected individuals. The VLPs were stable in suspension at 4 °C for at least 10 weeks. Mice immunized with VLPs developed neutralizing antibodies against lentiviruses pseudotyped with the SARS-CoV-2 spike protein. The flexibility of the VLP-production platform was demonstrated by the rapid switch of the spike protein to a new variant of concern (BA.1/Omicron). The present study describes an efficient, scalable, and adaptable production method of immunogenic SARS-CoV-2 VLPs with therapeutic potential." @default.
- W4386601467 created "2023-09-12" @default.
- W4386601467 creator A5003709171 @default.
- W4386601467 creator A5005904084 @default.
- W4386601467 creator A5007085188 @default.
- W4386601467 creator A5014969705 @default.
- W4386601467 creator A5017467492 @default.
- W4386601467 creator A5037269035 @default.
- W4386601467 creator A5038168171 @default.
- W4386601467 creator A5039873683 @default.
- W4386601467 creator A5050238342 @default.
- W4386601467 creator A5060539211 @default.
- W4386601467 creator A5063475491 @default.
- W4386601467 creator A5064030095 @default.
- W4386601467 creator A5065916156 @default.
- W4386601467 creator A5065955002 @default.
- W4386601467 creator A5070367937 @default.
- W4386601467 creator A5070955365 @default.
- W4386601467 creator A5088146082 @default.
- W4386601467 creator A5089940050 @default.
- W4386601467 creator A5091887836 @default.
- W4386601467 creator A5092844619 @default.
- W4386601467 creator A5092844620 @default.
- W4386601467 creator A5092844621 @default.
- W4386601467 date "2023-09-09" @default.
- W4386601467 modified "2023-10-17" @default.
- W4386601467 title "An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line" @default.
- W4386601467 cites W2005275397 @default.
- W4386601467 cites W2067653648 @default.
- W4386601467 cites W2099957667 @default.
- W4386601467 cites W2103951982 @default.
- W4386601467 cites W2150712887 @default.
- W4386601467 cites W2158771952 @default.
- W4386601467 cites W2167279371 @default.
- W4386601467 cites W2233551961 @default.
- W4386601467 cites W2804486665 @default.
- W4386601467 cites W3001897055 @default.
- W4386601467 cites W3003217347 @default.
- W4386601467 cites W3008827533 @default.
- W4386601467 cites W3009912996 @default.
- W4386601467 cites W3010955108 @default.
- W4386601467 cites W3013186573 @default.
- W4386601467 cites W3017680297 @default.
- W4386601467 cites W3025274120 @default.
- W4386601467 cites W3027763376 @default.
- W4386601467 cites W3033285830 @default.
- W4386601467 cites W3036931136 @default.
- W4386601467 cites W3046736440 @default.
- W4386601467 cites W3047135833 @default.
- W4386601467 cites W3049142173 @default.
- W4386601467 cites W3083130172 @default.
- W4386601467 cites W3093482635 @default.
- W4386601467 cites W3095932762 @default.
- W4386601467 cites W3103021984 @default.
- W4386601467 cites W3106737244 @default.
- W4386601467 cites W3112931438 @default.
- W4386601467 cites W3120174776 @default.
- W4386601467 cites W3121890661 @default.
- W4386601467 cites W3126619749 @default.
- W4386601467 cites W3132217836 @default.
- W4386601467 cites W3161351685 @default.
- W4386601467 cites W3165593231 @default.
- W4386601467 cites W3181480865 @default.
- W4386601467 cites W3198459714 @default.
- W4386601467 cites W3200289956 @default.
- W4386601467 cites W3209178111 @default.
- W4386601467 cites W4205532704 @default.
- W4386601467 cites W4206268572 @default.
- W4386601467 cites W4225012653 @default.
- W4386601467 cites W4229072469 @default.
- W4386601467 cites W4295781059 @default.
- W4386601467 cites W4296955286 @default.
- W4386601467 cites W4310031688 @default.
- W4386601467 cites W4311236123 @default.
- W4386601467 doi "https://doi.org/10.3390/vaccines11091469" @default.
- W4386601467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37766145" @default.
- W4386601467 hasPublicationYear "2023" @default.
- W4386601467 type Work @default.
- W4386601467 citedByCount "0" @default.
- W4386601467 crossrefType "journal-article" @default.
- W4386601467 hasAuthorship W4386601467A5003709171 @default.
- W4386601467 hasAuthorship W4386601467A5005904084 @default.
- W4386601467 hasAuthorship W4386601467A5007085188 @default.
- W4386601467 hasAuthorship W4386601467A5014969705 @default.
- W4386601467 hasAuthorship W4386601467A5017467492 @default.
- W4386601467 hasAuthorship W4386601467A5037269035 @default.
- W4386601467 hasAuthorship W4386601467A5038168171 @default.
- W4386601467 hasAuthorship W4386601467A5039873683 @default.
- W4386601467 hasAuthorship W4386601467A5050238342 @default.
- W4386601467 hasAuthorship W4386601467A5060539211 @default.
- W4386601467 hasAuthorship W4386601467A5063475491 @default.
- W4386601467 hasAuthorship W4386601467A5064030095 @default.
- W4386601467 hasAuthorship W4386601467A5065916156 @default.
- W4386601467 hasAuthorship W4386601467A5065955002 @default.
- W4386601467 hasAuthorship W4386601467A5070367937 @default.
- W4386601467 hasAuthorship W4386601467A5070955365 @default.
- W4386601467 hasAuthorship W4386601467A5088146082 @default.
- W4386601467 hasAuthorship W4386601467A5089940050 @default.